50 years Gelofusine®

The moon requires about 27 days to orbit the earth. In 27 days, 550,000 life-saving applications are done with Gelofusine®.

The colloidal volume replacement fluid Gelofusine® is characterized by proven pharmaceutical quality and demonstrated therapeutical value. In terms of figures: Gelofusine® represents the sum of

- 14 administrations per minute or
- 550,000 medications in one single lunar phase or
- 77 Million life saving applications within the last 10 years.

Gelofusine® – does not make the sun spinning around the earth, but enables patients to experience the next new moon ...

B|BRAUN
SHARING EXPERTISE

B. Braun Melsungen AG | Hospital Care | 34209 Melsungen | Germany
Tel. +49 5661 71-0 | www.bbraun.com

Gelofusine®
Composition: 1000 ml solution contain: Succinylated gelatin (= modified fluid gelatin) 40.00 g (Molecular weight, weight average: 30.000 Dalton; Molecular weight, number average: 23.200 Dalton) Sodium chloride 7.01 g; Electrolyte concentrations: Sodium 154 mmol/l, Chloride 120 mmol/l, Theoretical osmolarity: 274 mOsm/l, pH: 7.4 ± 0.3 **Therapeutic Indications:** Colloidal plasma volume substitute for Prophylaxis and treatment of relative or absolute hypovolaemia and of shock; Prophylaxis of hypotension (e.g. during induction of epidural or spinal anaesthesia); Procedures involving extracorporeal circulation (e.g. heart-lung machine); Acute normovolaemic haemodilution. **Contraindications:** Gelofusine® must not be administered in case of: hypersensitivity to any of the constituents of the solution, hypervolaemia, hyperhydration, severe cardiac insufficiency, severe blood coagulation disorders. **Special warnings and precautions for use:** Gelofusine® should be administered with caution to patients with a history of allergic diseases, e.g. asthma. Gelofusine® should only be administered with caution to elderly patients, patients at risk due to circulatory overload e.g., patients with congestive heart failure, right or left ventricular insufficiency, hypertension, pulmonary oedema or renal insufficiency with oligo- or anuria. In such cases Gelofusine® should only be given under careful monitoring of the patient's haemodynamic situation. **Undesirable Effects:** After the administration of Gelofusine® infusions, just as of any colloidal volume substitutes, ana-phylactoid reactions of varying degrees of severity may occur. The incidence of undesirable effects of Gelofusine® is as follows: Rare: anaphylactoid reactions all grades. Very rare: Severe anaphylactoid reactions. Uncommon: Transient mild nausea or abdominal pain, Transient mild rise of body temperature. **B. Braun Melsungen AG, 34212 Melsungen, Germany**